# WIA-GENOME_EDITING: Phase 1 - Data Format Specification

**Version:** 1.0
**Status:** FULL Implementation
**Last Updated:** 2026-01-12

---

## 1. Overview

This specification defines standardized data formats for genome editing workflows, including sequence representation, edit operations, validation results, and therapeutic outcomes.

### 1.1 Design Principles

- **Precision**: Exact base-level specification of edits
- **Interoperability**: Compatible with major bioinformatics tools
- **Traceability**: Complete audit trail of all editing operations
- **Safety**: Built-in validation and off-target detection
- **Clinical**: Support for therapeutic applications (Casgevy, gene therapy)

### 1.2 Scope

This phase covers:
- Genomic sequence data formats
- CRISPR-Cas9 guide RNA specifications
- Base editing and prime editing formats
- Validation and quality metrics
- Clinical outcome tracking

---

## 2. Core Data Structures

### 2.1 Genome Sequence Format

```json
{
  "sequence": {
    "id": "SEQ-2026-001",
    "type": "genomic_dna",
    "organism": "Homo sapiens",
    "chromosome": "11",
    "start_position": 5227002,
    "end_position": 5229395,
    "strand": "+",
    "sequence_data": "ATGGTGCATCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAG...",
    "gene_symbol": "HBB",
    "gene_name": "hemoglobin subunit beta",
    "reference_genome": "GRCh38.p14",
    "quality_score": 99.8,
    "coverage_depth": 150,
    "timestamp": "2026-01-12T10:30:00Z",
    "metadata": {
      "patient_id": "PT-SCD-001",
      "condition": "sickle_cell_disease",
      "mutation": "HbS (E6V)",
      "severity": "severe"
    }
  }
}
```

### 2.2 CRISPR-Cas9 Guide RNA Format

```json
{
  "guide_rna": {
    "id": "gRNA-HBB-001",
    "target_gene": "HBB",
    "sequence": "GTGCACCTGACTCCTGAGGAGAA",
    "pam_sequence": "AGG",
    "pam_position": "3prime",
    "cas_enzyme": "SpCas9",
    "chromosome": "11",
    "genomic_position": 5227020,
    "strand": "+",
    "edit_type": "double_strand_break",
    "design_score": 95.2,
    "specificity_score": 98.5,
    "on_target_score": 97.3,
    "off_target_sites": [
      {
        "chromosome": "15",
        "position": 8234501,
        "mismatches": 3,
        "score": 12.4
      }
    ],
    "predicted_efficiency": 89.5,
    "validation_status": "experimentally_validated",
    "design_tool": "CRISPOR",
    "designer": "Dr. Jennifer Chen",
    "design_date": "2026-01-10"
  }
}
```

### 2.3 Base Editing Format

```json
{
  "base_edit": {
    "id": "BE-HBB-E6V-001",
    "edit_type": "adenine_base_editor",
    "editor_variant": "ABE8.20-m",
    "target_gene": "HBB",
    "target_codon": 6,
    "original_sequence": "GAG",
    "target_base": "A",
    "target_position": 5227021,
    "edited_base": "G",
    "edited_sequence": "GTG",
    "amino_acid_change": "E6V",
    "phenotype": "sickle_cell_to_normal",
    "editing_window": {
      "start": 4,
      "end": 8,
      "positions": [4, 5, 6, 7, 8]
    },
    "guide_rna": "GTGCACCTGACTCCTGAGGAGAA",
    "pam_sequence": "AGG",
    "predicted_efficiency": 75.3,
    "bystander_edits": [
      {
        "position": 5227018,
        "original": "A",
        "edited": "G",
        "effect": "silent_mutation",
        "frequency": 5.2
      }
    ],
    "off_target_analysis": {
      "total_sites_analyzed": 23500000000,
      "high_risk_sites": 0,
      "medium_risk_sites": 2,
      "low_risk_sites": 15
    },
    "validation": {
      "in_vitro_efficiency": 68.5,
      "in_vivo_efficiency": 45.2,
      "product_purity": 92.3,
      "unwanted_products": 3.1
    }
  }
}
```

### 2.4 Prime Editing Format

```json
{
  "prime_edit": {
    "id": "PE-HBB-001",
    "edit_type": "prime_editing",
    "editor_system": "PE5",
    "target_gene": "HBB",
    "edit_class": "substitution",
    "pegRNA": {
      "spacer": "GTGCACCTGACTCCTGAGGA",
      "pbs_length": 13,
      "pbs_sequence": "TCCTCAGGAGTCA",
      "rt_template_length": 16,
      "rt_template": "GTGCACCTGACTCCTG",
      "edit_position": 5,
      "replacement_sequence": "GTG"
    },
    "ngRNA": {
      "sequence": "CTGGGCAGGTTGGTATCAAG",
      "nick_distance": 65,
      "nick_strand": "non_edited"
    },
    "original_sequence": "...GTGCACCTGACTCCTGAGGAGAAG...",
    "edited_sequence": "...GTGCACCTGACTCCTGTGGAGAAG...",
    "mutation_corrected": "HbS_E6V",
    "predicted_efficiency": 52.8,
    "predicted_precision": 95.6,
    "indel_frequency": 2.1,
    "off_target_edits": {
      "total_analyzed": 1500,
      "detected": 3,
      "severity": "low"
    },
    "install_rate": 48.5,
    "byproduct_rate": 4.2
  }
}
```

### 2.5 Gene Therapy Format (Casgevy-style)

```json
{
  "gene_therapy": {
    "id": "GT-CASGEVY-001",
    "therapy_name": "exagamglogene autotemcel",
    "trade_name": "Casgevy",
    "indication": "beta_thalassaemia_transfusion_dependent",
    "regulatory_status": {
      "fda_approved": true,
      "approval_date": "2024-01-16",
      "ema_approved": true,
      "approval_number": "BLA-125755"
    },
    "mechanism": {
      "type": "BCL11A_enhancer_disruption",
      "target": "erythroid_enhancer_BCL11A",
      "chromosome": "2",
      "position": 60716189,
      "effect": "fetal_hemoglobin_reactivation",
      "editor": "CRISPR-Cas9"
    },
    "patient_info": {
      "id": "PT-TDT-005",
      "diagnosis": "transfusion_dependent_beta_thalassaemia",
      "genotype": "HBB_IVS-1-110(G>A)/IVS-1-110(G>A)",
      "baseline_hgb": 6.8,
      "transfusion_frequency": "every_3_weeks",
      "iron_overload": "severe"
    },
    "manufacturing": {
      "cell_source": "autologous_CD34+_HSPCs",
      "cell_count": 8.5e6,
      "viability": 97.2,
      "editing_efficiency": 78.5,
      "lot_number": "CASGEVY-2026-001",
      "manufacturing_site": "Vertex_Pharmaceuticals",
      "release_date": "2026-01-05"
    },
    "treatment_protocol": {
      "mobilization": {
        "agent": "plerixafor",
        "dose": "0.24_mg/kg",
        "schedule": "daily_for_5_days"
      },
      "apheresis": {
        "sessions": 2,
        "total_cd34_collected": 12.5e6
      },
      "conditioning": {
        "agent": "busulfan",
        "dose": "targeted_AUC",
        "duration": "4_days"
      },
      "infusion": {
        "cell_dose": 8.5e6,
        "infusion_date": "2026-01-08",
        "complications": "none"
      }
    },
    "outcomes": {
      "follow_up_months": 6,
      "engraftment_day": 23,
      "fetal_hemoglobin_percent": 42.5,
      "total_hemoglobin": 12.3,
      "transfusion_independence": true,
      "transfusion_free_days": 180,
      "adverse_events": [
        {
          "event": "febrile_neutropenia",
          "grade": 3,
          "onset_day": 8,
          "resolution_day": 15
        }
      ],
      "quality_of_life_score": 85.2,
      "patient_satisfaction": "very_satisfied"
    }
  }
}
```

### 2.6 Off-Target Detection Format

```json
{
  "off_target_analysis": {
    "id": "OT-ANALYSIS-001",
    "edit_id": "BE-HBB-E6V-001",
    "analysis_method": "GUIDE-seq",
    "analysis_date": "2026-01-11",
    "genome_wide_sites": 23500000000,
    "detected_sites": 17,
    "sites": [
      {
        "rank": 1,
        "chromosome": "11",
        "position": 5227021,
        "type": "on_target",
        "sequence": "GTGCACCTGACTCCTGAGGAGAA",
        "mismatches": 0,
        "bulges": 0,
        "read_count": 125800,
        "normalized_score": 100.0,
        "in_gene": true,
        "gene": "HBB",
        "consequence": "therapeutic_edit"
      },
      {
        "rank": 2,
        "chromosome": "15",
        "position": 8234501,
        "type": "off_target",
        "sequence": "GTGCACCTGACTGCTGAGGAGAA",
        "mismatches": 1,
        "bulges": 0,
        "read_count": 452,
        "normalized_score": 0.36,
        "in_gene": false,
        "gene": "intergenic",
        "consequence": "likely_benign",
        "risk_level": "low"
      },
      {
        "rank": 3,
        "chromosome": "7",
        "position": 15678234,
        "type": "off_target",
        "sequence": "GTGCACCTGAGTCCTGAGGAGAA",
        "mismatches": 1,
        "bulges": 0,
        "read_count": 287,
        "normalized_score": 0.23,
        "in_gene": true,
        "gene": "ENSG00000123456",
        "consequence": "intronic",
        "risk_level": "low"
      }
    ],
    "summary": {
      "total_off_targets": 16,
      "high_risk": 0,
      "medium_risk": 2,
      "low_risk": 14,
      "safety_score": 96.8,
      "recommendation": "proceed_with_caution"
    }
  }
}
```

---

## 3. Validation Metrics

### 3.1 Edit Validation Format

```json
{
  "validation": {
    "id": "VAL-001",
    "edit_id": "BE-HBB-E6V-001",
    "validation_method": "next_generation_sequencing",
    "sequencing_depth": 50000,
    "validation_date": "2026-01-12",
    "results": {
      "on_target_efficiency": 68.5,
      "precision": 95.2,
      "allele_frequencies": {
        "wildtype": 24.8,
        "edited": 68.5,
        "indels": 2.1,
        "other": 4.6
      },
      "indel_spectrum": {
        "1bp_deletion": 1.2,
        "1bp_insertion": 0.5,
        "2bp_deletion": 0.3,
        "other": 0.1
      },
      "product_purity": 92.3,
      "bystander_editing": 5.2
    },
    "quality_control": {
      "sequence_quality": "pass",
      "coverage_uniformity": "pass",
      "strand_bias": "none",
      "pcr_duplicates": 2.3,
      "mapping_quality": 98.5
    },
    "clinical_significance": {
      "therapeutic_efficacy": "high",
      "safety_profile": "acceptable",
      "approval_status": "recommended"
    }
  }
}
```

### 3.2 Safety Assessment Format

```json
{
  "safety_assessment": {
    "id": "SAFETY-001",
    "edit_id": "BE-HBB-E6V-001",
    "assessment_date": "2026-01-12",
    "genotoxicity": {
      "chromosomal_aberrations": "none_detected",
      "micronucleus_frequency": 0.8,
      "dna_damage_score": 2.1,
      "p53_activation": "negative"
    },
    "immunogenicity": {
      "anti_cas9_antibodies": "negative",
      "t_cell_response": "minimal",
      "inflammatory_markers": "within_normal_range"
    },
    "off_target_impacts": {
      "total_analyzed": 17,
      "functional_impact": "none",
      "oncogene_proximity": "none",
      "tumor_suppressor_impact": "none"
    },
    "cell_viability": {
      "post_edit_viability": 94.5,
      "proliferation_rate": "normal",
      "apoptosis_rate": 3.2,
      "differentiation_capacity": "intact"
    },
    "overall_risk": "low",
    "recommendation": "approved_for_clinical_use"
  }
}
```

---

## 4. Clinical Data Format

### 4.1 Patient Treatment Record

```json
{
  "clinical_record": {
    "record_id": "CR-2026-001",
    "patient_id": "PT-SCD-001",
    "condition": "sickle_cell_disease",
    "treatment": {
      "therapy_id": "GT-CASGEVY-001",
      "treatment_date": "2026-01-08",
      "treating_physician": "Dr. Sarah Johnson",
      "institution": "Boston Children's Hospital",
      "protocol_version": "CASGEVY-v2.0"
    },
    "baseline_data": {
      "age": 28,
      "sex": "female",
      "weight_kg": 65.5,
      "disease_duration_years": 26,
      "vaso_occlusive_crises_per_year": 8,
      "hospitalizations_per_year": 4,
      "baseline_hgb": 7.2,
      "hgb_f_percent": 2.1,
      "transfusions_lifetime": 45
    },
    "follow_up": [
      {
        "day": 30,
        "total_hgb": 8.9,
        "hgb_f_percent": 18.5,
        "crises": 0,
        "transfusions": 0,
        "adverse_events": "grade_2_mucositis"
      },
      {
        "day": 90,
        "total_hgb": 11.2,
        "hgb_f_percent": 35.8,
        "crises": 0,
        "transfusions": 0,
        "adverse_events": "none"
      },
      {
        "day": 180,
        "total_hgb": 12.3,
        "hgb_f_percent": 42.5,
        "crises": 0,
        "transfusions": 0,
        "adverse_events": "none",
        "qol_score": 85.2,
        "employment_status": "full_time"
      }
    ],
    "outcomes": {
      "transfusion_independence": true,
      "transfusion_free_days": 180,
      "crisis_free": true,
      "hospitalization_free": true,
      "quality_of_life_improvement": 125.3,
      "treatment_success": true
    }
  }
}
```

---

## 5. File Format Standards

### 5.1 Sequence File Formats

- **FASTA**: Reference sequences
- **FASTQ**: Raw sequencing data
- **BAM/SAM**: Aligned sequencing reads
- **VCF**: Variant calling
- **BED**: Genomic regions

### 5.2 Data Exchange Formats

- **JSON**: Primary API format
- **XML**: Legacy system compatibility
- **CSV/TSV**: Tabular data export
- **HDF5**: Large-scale genomic data

### 5.3 Metadata Standards

- **ISO 8601**: Timestamps
- **HGNC**: Gene nomenclature
- **HGVS**: Variant nomenclature
- **LOINC**: Laboratory observations
- **SNOMED CT**: Clinical terminology

---

## 6. Quality Standards

### 6.1 Sequence Quality

- Minimum Phred score: Q30 (99.9% accuracy)
- Minimum coverage depth: 100x for clinical applications
- Mapping quality: ≥60
- Strand balance: 0.3-0.7

### 6.2 Edit Quality

- On-target efficiency: ≥50% for therapeutic applications
- Precision: ≥90% (ratio of desired to total edits)
- Indel frequency: ≤5%
- Off-target activity: ≤1% of on-target

### 6.3 Clinical Quality

- Patient identification: HIPAA-compliant
- Data integrity: SHA-256 checksums
- Audit trail: Complete provenance tracking
- Regulatory compliance: FDA 21 CFR Part 11

---

## 7. API Compatibility

### 7.1 Integration Points

- **NCBI RefSeq**: Reference genome data
- **ClinVar**: Variant clinical significance
- **COSMIC**: Cancer mutations
- **gnomAD**: Population allele frequencies
- **ENCODE**: Regulatory elements

### 7.2 Tool Compatibility

- **CRISPOR**: Guide RNA design
- **Benchling**: Molecular biology platform
- **Geneious**: Sequence analysis
- **IGV**: Genome visualization
- **DeepVariant**: Variant calling

---

## 8. Security and Privacy

### 8.1 Data Encryption

- At rest: AES-256
- In transit: TLS 1.3
- Key management: HSM or KMS

### 8.2 Access Control

- Authentication: OAuth 2.0 / SAML
- Authorization: RBAC with ABAC
- Audit logging: Immutable logs

### 8.3 Compliance

- HIPAA: Health Insurance Portability and Accountability Act
- GDPR: General Data Protection Regulation
- FDA: 21 CFR Part 11
- CLIA: Clinical Laboratory Improvement Amendments

---

## 9. Version History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2026-01-12 | Initial FULL specification release |

---

## 10. References

1. FDA Approval - Casgevy (exagamglogene autotemcel), 2024
2. Anzalone et al., "Search-and-replace genome editing", Nature, 2019
3. Gaudelli et al., "Programmable base editing of A•T to G•C", Nature, 2017
4. Komor et al., "Programmable editing of a target base", Nature, 2016
5. Frangoul et al., "Exagamglogene autotemcel for sickle cell disease", NEJM, 2021

---

**Document Control:**
- Classification: Public
- Jurisdiction: International
- Maintained by: WIA Technical Committee
- Review cycle: Quarterly

© 2026 WIA (World Certification Industry Association)
弘益人間 (홍익인간) - Benefit All Humanity
